nach oben

Current Oncology Reports

Erschienen in:

01.07.2019 | Breast Cancer (B Overmoyer, Section Editor)

Issues with Fertility in Young Women with Breast Cancer

verfasst von: Nicole Christian, Mary L. Gemignani

Erschienen in: Current Oncology Reports | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

There are competing risks and benefits of cancer therapies and fertility preservation in young women with breast cancer. Here we discuss the impact of therapy on fertility, fertility preservation options, and emerging information in fertility issues for the breast cancer patient.

Recent Findings

All systemic forms of breast cancer treatment can impact future fertility. Pre-therapy fertility preservation may offer the best opportunity for future fertility. Shared decision making with the individual patient and clinical scenario is important. Early referral to a fertility specialist should be offered to young patients.

Summary

We find that fertility preservation options for young women diagnosed with breast cancer are currently available, but potentially under-utilized. We conclude that a multidisciplinary approach is necessary, with discussion of potential risks and benefits of fertility preservation options in the context of the patient’s clinical disease.

Hery C, Ferlay J, Boniol M, Autier P. Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations. Ann Oncol. 2008;19(5):1009–18. https://doi.org/10.1093/annonc/mdm593.CrossRefPubMed

Merlo DF, Ceppi M, Filiberti R, et al. Breast cancer incidence trends in European women aged 20–39 years at diagnosis. Breast Cancer Res Treat. 2012;134(1):363–70. https://doi.org/10.1007/s10549-012-2031-7.CrossRefPubMed

Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. Semin Oncol. 2009;36(3):237–49. https://doi.org/10.1053/j.seminoncol.2009.03.001.CrossRefPubMedPubMedCentral

Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat. 2009;113(2):357–70. https://doi.org/10.1007/s10549-008-9926-3.CrossRefPubMed

Kollias J, Elston CW, Ellis IO, Robertson JF, Blamey RW. Early-onset breast cancer--histopathological and prognostic considerations. Br J Cancer. 1997;75(9):1318–23. http://www.ncbi.nlm.nih.gov/pubmed/9155052. Accessed 30 Jan 2019.CrossRef

Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg. 2009;208(3):341–7. https://doi.org/10.1016/j.jamcollsurg.2008.12.001.CrossRefPubMedPubMedCentral

Chen H, Zhou M, Tian W, Meng K, He H. Effect of Age on Breast Cancer Patient Prognoses: A Population-Based Study Using the SEER 18 Database. Coleman WB, ed. PLoS One. 2016;11(10):e0165409. doi:https://doi.org/10.1371/journal.pone.0165409.CrossRef

Meirow D, Schiff E. Appraisal of chemotherapy effects on reproductive outcome according to animal studies and clinical data. J Natl Cancer Inst Monogr. 2005;2005(34):21–5. https://doi.org/10.1093/jncimonographs/lgi025.CrossRef

Maltaris T, Boehm D, Dittrich R, Seufert R, Koelbl H. Reproduction beyond cancer: A message of hope for young women 2006. doi:https://doi.org/10.1016/j.ygyno.2006.08.003.CrossRef

10.

NCCN. Pregnancy after cancer. https://www.nccn.org/patients/resources/life_after_cancer/pregnancy.aspx. Accessed 17 Feb 2019.

11.

Pagani O, Ruggeri M, Manunta S, Saunders C, Peccatori F, Cardoso F, et al. Pregnancy after breast cancer: are young patients willing to participate in clinical studies? Breast. 2015;24(3):201–7. https://doi.org/10.1016/j.breast.2015.01.005.CrossRefPubMed

12.

Henry NL, Xia R, Schott AF, McConnell D, Banerjee M, Hayes DF. Prediction of postchemotherapy ovarian function using markers of ovarian reserve. Oncologist. 2014;19(1):68–74. https://doi.org/10.1634/theoncologist.2013-0145.CrossRefPubMed

13.

Rossi L, Pagani O. Impact of breast cancer treatment on fertility. In: Breast Cancer, fertility preservation and reproduction. Cham: Springer International Publishing; 2015. p. 29–43. https://doi.org/10.1007/978-3-319-17278-1_3.CrossRef

14.

Jung M, Shin HJ, Rha SY, Jeung HC, Hong S, Moon YW, et al. The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up. Ann Surg Oncol. 2010;17(12):3259–68. https://doi.org/10.1245/s10434-010-1172-3.CrossRefPubMed

15.

Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer. 2007;110(10):2222–9. https://doi.org/10.1002/cncr.23071.CrossRefPubMed

16.

Morgan S, Anderson RA, Gourley C, Wallace WH, Spears N. How do chemotherapeutic agents damage the ovary? Hum Reprod Update. 2012;18(5):525–35. https://doi.org/10.1093/humupd/dms022.CrossRefPubMed

17.

Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control. 2002;9(6):466–72. https://doi.org/10.1177/107327480200900603.CrossRefPubMed

18.

Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005;104(8):1575–9. https://doi.org/10.1002/cncr.21385.CrossRefPubMed

19.

Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update. 7(6):535–43. http://www.ncbi.nlm.nih.gov/pubmed/11727861. Accessed 30 Jan 2019.CrossRef

20.

•• Zhao J, Liu J, Chen K, et al. What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis. Breast Cancer Res Treat. 2014;145(1):113–28. https://doi.org/10.1007/s10549-014-2914-x. A recent meta-analysis on the impact of multiple types of chemotherapy on chemotherapy-induced amenorrhea. Review and synthesis of available data.CrossRefPubMed

21.

Zagouri F, Sergentanis TN, Chrysikos D, Papadimitriou CA, Dimopoulos M-A, Bartsch R. Trastuzumab administration during pregnancy: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;137(2):349–57. https://doi.org/10.1007/s10549-012-2368-y.CrossRefPubMed

22.

Rosenberg SM, Partridge AH. Management of breast cancer in very young women. Breast. 2015;24:S154–8. https://doi.org/10.1016/j.breast.2015.07.036.CrossRefPubMed

23.

Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255–69. https://doi.org/10.1200/JCO.2013.54.2258.CrossRefPubMedPubMedCentral

24.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16. https://doi.org/10.1016/S0140-6736(12)61963-1.CrossRefPubMedPubMedCentral

25.

Gray RG, Rea D, Handley K, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013;31(18_suppl):5. https://doi.org/10.1200/jco.2013.31.18_suppl.5.CrossRef

26.

Braems G, Denys H, De Wever O, Cocquyt V, Van den Broecke R. Use of tamoxifen before and during pregnancy. Oncologist. 2011;16(11):1547–51. https://doi.org/10.1634/theoncologist.2011-0121.CrossRefPubMedPubMedCentral

27.

Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast Cancer. N Engl J Med. 2015;372(5):436–46. https://doi.org/10.1056/NEJMoa1412379.CrossRefPubMed

28.

•• Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122–37. https://doi.org/10.1056/NEJMoa1803164. Long-term follow-up of the SOFT and TEXT trials, demonstrating ovarian suppression with tamoxifen is superior to tamoxifen alone, and exemestane with ovarian suppression is superior to tamoxifen with ovarian suppression.CrossRefPubMedPubMedCentral

29.

Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, et al. Adjuvant Exemestane with ovarian suppression in premenopausal breast Cancer. N Engl J Med. 2014;371(2):107–18. https://doi.org/10.1056/NEJMoa1404037.CrossRefPubMedPubMedCentral

30.

•• Saha P, Regan MM, Pagani O, et al. Treatment efficacy, adherence, and quality of life among women younger than 35 years in the International Breast Cancer Study Group TEXT and SOFT adjuvant endocrine therapy trials. J Clin Oncol. 2017;35(27):3113–22. https://doi.org/10.1200/JCO.2016.72.0946. Young (age < 35 years) premenopausal women with ER+ cancers experience similar symptoms to tamoxifen and ovarian suppression to older women. Approximately 20% of these premenopausal patients stop recommended therapy because of symptoms.CrossRefPubMedPubMedCentral

31.

Rosenberg SM, Gelber S, Gelber RD, Krop E, Korde LA, Pagani O, et al. Oncology physicians’ perspectives on practices and barriers to fertility preservation and the feasibility of a prospective study of pregnancy after breast cancer. J Adolesc Young Adult Oncol. 2017;6(3):429–34. https://doi.org/10.1089/jayao.2017.0031.CrossRefPubMedPubMedCentral

32.

Lambertini M, Ceppi M, Poggio F, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015;26(12):mdv374. https://doi.org/10.1093/annonc/mdv374.CrossRef

33.

Armstrong DK, Ω C, Plaxe SC, et al. NCCN Guidelines Version 2.2018 Ovarian Cancer Continue.; 2019. www.nccn.org/patients. Accessed 30 Jan 2019.

34.

Stroud JS, Mutch D, Rader J, Powell M, Thaker PH, Grigsby PW. Effects of cancer treatment on ovarian function. Fertil Steril. 2009;92(2):417–27. https://doi.org/10.1016/j.fertnstert.2008.07.1714.CrossRefPubMed

35.

Peate M, Meiser B, Friedlander M, Zorbas H, Rovelli S, Sansom-Daly U, et al. It’s now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer--an Australian fertility decision aid collaborative group study. J Clin Oncol. 2011;29(13):1670–7. https://doi.org/10.1200/JCO.2010.31.2462.CrossRefPubMed

36.

Jukkala AM, Azuero A, McNees P, Bates GW, Meneses K. Self-assessed knowledge of treatment and fertility preservation in young women with breast cancer. Fertil Steril. 2010;94(6):2396–8. https://doi.org/10.1016/j.fertnstert.2010.03.043.CrossRefPubMed

37.

Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22(20):4174–83. https://doi.org/10.1200/JCO.2004.01.159.CrossRefPubMed

38.

Baynosa J, Westphal LM, Madrigrano A, Wapnir I. Timing of breast cancer treatments with oocyte retrieval and embryo cryopreservation. J Am Coll Surg. 2009;209(5):603–7. https://doi.org/10.1016/j.jamcollsurg.2009.08.006.CrossRefPubMed

39.

Goldfarb SB, Kamer SA, Oppong BA, Eaton A, Patil S, Junqueira MJ, et al. Fertility preservation for the young breast cancer patient. Ann Surg Oncol. 2016;23(5):1530–6. https://doi.org/10.1245/s10434-015-5036-8.CrossRefPubMedPubMedCentral

40.

Anderson RA, Cameron DA. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab. 2011;96(5):1336–43. https://doi.org/10.1210/jc.2010-2582.CrossRefPubMed

41.

Ruddy KJ, O’Neill A, Miller KD, Schneider BP, Baker E, Sparano JA, et al. Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. Breast Cancer Res Treat. 2014;144(3):591–7. https://doi.org/10.1007/s10549-014-2891-0.CrossRefPubMedPubMedCentral

42.

Scheffer GJ, Broekmans FJM, Looman CWN, Blankenstein M, Fauser BC, teJong F, et al. The number of antral follicles in normal women with proven fertility is the best reflection of reproductive age. Hum Reprod. 2003;18(4):700–6. http://www.ncbi.nlm.nih.gov/pubmed/12660259. Accessed 30 Jan 2019.CrossRef

43.

Kasum M, Šimunić V, Orešković S, Beketić-Orešković L. Fertility preservation with ovarian stimulation protocols prior to cancer treatment. Gynecol Endocrinol. 2014;30(3):182–6. https://doi.org/10.3109/09513590.2013.860123.CrossRefPubMed

44.

Revelli A, Salvagno F, Casano S, Piane LD, Benedetto C. Fertility preservation, ART, and breast cancer. In: Breast cancer, fertility preservation and reproduction. Cham: Springer International Publishing; 2015. p. 45–59. https://doi.org/10.1007/978-3-319-17278-1_4.CrossRef

45.

Reddy J, Oktay K. Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer. Fertil Steril. 2012;98(6):1363–9. https://doi.org/10.1016/j.fertnstert.2012.09.022.CrossRefPubMed

46.

Rodriguez-Wallberg KA, Oktay K. Fertility preservation in women with breast cancer. Clin Obstet Gynecol. 2010;53(4):753–62. https://doi.org/10.1097/GRF.0b013e3181f96e00.CrossRefPubMedPubMedCentral

47.

•• Rodriguez-Wallberg KA, Eloranta S, Krawiec K, Lissmats A, Bergh J, Liljegren A. Safety of fertility preservation in breast cancer patients in a register-based matched cohort study. Breast Cancer Res Treat. 2018;167(3):761–9. https://doi.org/10.1007/s10549-017-4555-3. A cohort/registry study that identifies fertility preservation protocols with hormone stimulation are not associated with worse oncologic outcomes compared to fertility preservation without hormone stimulation.CrossRefPubMed

48.

•• Rodgers RJ, Reid GD, Koch J, et al. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. Hum Reprod. 2017;32(5):1033–45. https://doi.org/10.1093/humrep/dex027. A meta-analysis of the literature which did not find differences in disease-specific recurrence and survival for patients undergoing ovarian hyperstimulation compared to those who did not for fertility preservation.CrossRefPubMed

49.

Lee S, Ozkavukcu S, Heytens E, Moy F, Oktay K. Value of early referral to fertility preservation in young women with breast cancer. J Clin Oncol. 2010;28(31):4683–6. https://doi.org/10.1200/JCO.2010.30.5748.CrossRefPubMedPubMedCentral

50.

Rodriguez-Wallberg KA, Oktay K. Fertility preservation and pregnancy in women with and without BRCA mutation–positive breast cancer. Oncologist. 2012;17(11):1409–17. https://doi.org/10.1634/theoncologist.2012-0236.CrossRefPubMedPubMedCentral

51.

van Tilborg TC, Broekmans FJ, Pijpe A, Schrijver LH, Mooij TM, Oosterwijk JC, et al. Do BRCA1/2 mutation carriers have an earlier onset of natural menopause? Menopause. 2016;23(8):903–10. https://doi.org/10.1097/GME.0000000000000633.CrossRefPubMed

52.

•• Derks-Smeets IAP, de Die-Smulders CEM, Mackens S, et al. Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors. Breast Cancer Res Treat. 2014;145(3):673–81. https://doi.org/10.1007/s10549-014-2951-5. An observational study on the effectiveness of pre-implantation genetic diagnosis for a cohort of BRCA mutation carriers, and results of successful pregnancies.CrossRefPubMed

Titel: Issues with Fertility in Young Women with Breast Cancer
verfasst von: Nicole Christian
Mary L. Gemignani
Publikationsdatum: 01.07.2019
Verlag: Springer US
Erschienen in: Current Oncology Reports / Ausgabe 7/2019
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-019-0812-4

Neu im Fachgebiet Onkologie

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Issues with Fertility in Young Women with Breast Cancer

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Onkologie

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

Das sind die führenden Symptome junger Darmkrebspatienten

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2019

Management of Newly Diagnosed Elderly Multiple Myeloma Patients

Correction to: Systemic Therapy of Central Nervous System Metastases of Breast Cancer

Is It Time to Revisit the Role of Allogeneic Transplantation in Lymphoma?

Follicular Lymphoma: Diagnostic and Prognostic Considerations in Initial Treatment Approach

Targeted Therapies for the Treatment of Glioblastoma in Adults

Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim–Chester Disease, Destombes–Rosai–Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders

Neu im Fachgebiet Onkologie

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

Das sind die führenden Symptome junger Darmkrebspatienten

Update Onkologie